(Q44498935)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22549247%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

title

Topical and systemic medications for the treatment of primary Sjögren's syndrome (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22549247%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22549247%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

Pilar Brito Zerón

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22549247%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

Antoni Sisó-Almirall

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22549247%20AND%20SRC:MED&resulttype=core&format=json

Athanasios George Tzioufas

30 January 2020

5

object named as

Athanasios G Tzioufas

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22549247%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

author name string

Xavier Bosch

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22549247%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

language of work or name

English

0 references

publication date

1 May 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22549247%20AND%20SRC:MED&resulttype=core&format=json

Nature Reviews Rheumatology

30 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22549247%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

volume

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22549247%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

issue

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22549247%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

page(s)

399-411

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22549247%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/nrrheum.2012.53

30 January 2020

exact match

0 references

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.53

Clinical manifestations and early diagnosis of Sjögren syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.53

Treatment of primary Sjögren syndrome: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.53

Effects of mouthrinses with linseed extract Salinum without/with chlorhexidine on oral conditions in patients with Sjögren's syndrome. A double-blind crossover investigation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.53

Sodium hyaluronate eye drops of different osmolarity for the treatment of dry eye in Sjögren's syndrome patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.53

Long term treatment with sodium hyaluronate-containing artificial tears reduces ocular surface damage in patients with dry eye

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.53

Efficacy and safety of 0.18% sodium hyaluronate in patients with moderate dry eye syndrome and superficial keratitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.53

Double blind, randomised, placebo controlled, crossover, multicentre study to determine the efficacy of a 0.1% (w/v) sodium hyaluronate solution (Fermavisc) in the treatment of dry eye syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.53

A randomised, crossover, multicentre study to compare the performance of 0.1% (w/v) sodium hyaluronate with 1.4% (w/v) polyvinyl alcohol in the alleviation of symptoms associated with dry eye syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.53

Effects of the topical treatment with NSAIDs on corneal sensitivity and ocular surface of Sjögren's syndrome patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.53

Keratitis, ulceration, and perforation associated with topical nonsteroidal anti-inflammatory drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.53

The comparison of efficacies of topical corticosteroids and nonsteroidal anti-inflammatory drops on dry eye patients: a clinical and immunocytochemical study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.53

Topical nonpreserved methylprednisolone therapy for keratoconjunctivitis sicca in Sjögren syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.53

A randomized, double-masked, placebo-controlled, multicenter comparison of loteprednol etabonate ophthalmic suspension, 0.5%, and placebo for treatment of keratoconjunctivitis sicca in patients with delayed tear clearance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.53

High-frequency topical cyclosporine 0.05% in the treatment of severe dry eye refractory to twice-daily regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.53

Comparison of topical cyclosporine, punctal occlusion, and a combination for the treatment of dry eye.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.53

An evaluation of the efficacy of a cyclosporine-based dry eye therapy when used with marketed artificial tears as supportive therapy in dry eye.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.53

Efficacy and safety of cyclosporin A ophthalmic emulsion in the treatment of moderate-to-severe dry eye disease: a dose-ranging, randomized trial. The Cyclosporin A Phase 2 Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.53

Corneal and conjunctival sensitivity in patients with dry eye: the effect of topical cyclosporine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.53

Evaluation of topical cyclosporine for the treatment of dry eye disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.53

Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.53

A comparison of vitamin a and cyclosporine a 0.05% eye drops for treatment of dry eye syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.53

Phase III safety evaluation of cyclosporine 0.1% ophthalmic emulsion administered twice daily to dry eye disease patients for up to 3 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.53

Double-masked, placebo-controlled safety and efficacy trial of diquafosol tetrasodium (INS365) ophthalmic solution for the treatment of dry eye.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.53

Conjunctival epithelium improvement after systemic pilocarpine in patients with Sjogren's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.53

A controlled release pilocarpine buccal insert in the treatment of Sjögren's syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.53

Successful Treatment of Dry Mouth and Dry Eye Symptoms in Sjögren's Syndrome Patients With Oral Pilocarpine: A Randomized, Placebo-Controlled, Dose-Adjustment Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.53

Usefulness of basal and pilocarpine-stimulated salivary flow in primary Sjögren's syndrome. Correlation with clinical, immunological and histological features

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.53

Oral pilocarpine for the treatment of ocular symptoms in patients with Sjögren's syndrome: a randomised 12 week controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.53

Pilocarpine hydrochloride for the treatment of xerostomia in patients with Sjögren's syndrome in Taiwan--a double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.53

Cevimeline for the treatment of xerostomia in patients with Sjögren syndrome: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.53

The efficacy of cevimeline hydrochloride in the treatment of xerostomia in Sjögren's syndrome in southern Chinese patients: a randomised double-blind, placebo-controlled crossover study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.53

Therapeutic effect of cevimeline on dry eye in patients with Sjögren's syndrome: a randomized, double-blind clinical study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.53

A double-blind, randomized, placebo-controlled study of cevimeline in Sjögren's syndrome patients with xerostomia and keratoconjunctivitis sicca

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.53

Effect of cevimeline on salivary components in patients with Sjögren syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.53

Parotid irrigation and cevimeline gargle for treatment of xerostomia in Sjögren's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.53

Corticosteroid irrigation of parotid gland for treatment of xerostomia in patients with Sjögren's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.53

Progression of salivary gland dysfunction in patients with Sjogren's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.53

Hydroxychloroquine treatment for primary Sjögren's syndrome: a two year double blind crossover trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.53

Hydroxychloroquine treatment for primary Sjögren's syndrome: its effect on salivary and serum inflammatory markers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.53

Treatment of sicca symptoms with hydroxychloroquine in patients with Sjogren's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.53

Treatment of primary Sjögren's syndrome with hydroxychloroquine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.53

Respiratory function in systemic lupus erythematosus: relation with activity and severity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.53

Effects of hydroxychloroquine on salivary flow rates and oral complaints of Sjögren patients: a prospective sample study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.53

Hydroxychloroquine improves dry eye symptoms of patients with primary Sjogren's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.53

Safety and efficacy of leflunomide in primary Sjögren's syndrome: a phase II pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.53

Mycophenolate sodium treatment in patients with primary Sjögren syndrome: a pilot trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.53

Prominent adverse effects of thalidomide in primary Sjögren's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.53

Usefulness of initial histological features for stratifying Sjogren's syndrome responders to mizoribine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.53

Effectiveness of low-dose doxycycline (LDD) on clinical symptoms of Sjögren's syndrome: a randomized, double-blind, placebo controlled cross-over study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.53

Pilot clinical trial of dehydroepiandrosterone (DHEA) versus placebo for Sjögren's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.53

Effect of dehydroepiandrosterone administration on fatigue, well-being, and functioning in women with primary Sjögren syndrome: a randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.53

Low serum levels of sex steroids are associated with disease characteristics in primary Sjogren's syndrome; supplementation with dehydroepiandrosterone restores the concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.53

Systemic omega-6 essential fatty acid treatment and pge1 tear content in Sjögren's syndrome patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.53

Gammalinolenic acid treatment of fatigue associated with primary Sjögren's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.53

A pilot study to test the efficacy of oral administration of interferon-alpha lozenges to patients with Sjögren's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.53

Inefficacy of infliximab in primary Sjögren's syndrome: results of the randomized, controlled Trial of Remicade in Primary Sjögren's Syndrome (TRIPSS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.53

Effectiveness of rituximab treatment in primary Sjögren's syndrome: a randomized, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.53

Reduction of fatigue in Sjögren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.53

Rituximab treatment in patients with primary Sjögren's syndrome: an open-label phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.53

Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjögren's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.53

Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.53

Long term remission of Sjögren's syndrome associated aggressive B cell non-Hodgkin's lymphomas following combined B cell depletion therapy and CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.53

Efficacy of rituximab in primary Sjogren's syndrome with peripheral nervous system involvement: results from the AIR registry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.53

Epratuzumab (humanised anti-CD22 antibody) in primary Sjögren's syndrome: an open-label phase I/II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.53

Comparison of autologous serum eye drops with conventional therapy in a randomised controlled crossover trial for ocular surface disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.53

Therapeutic targeting of B cells for rheumatic autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.53

Evolución y pronóstico del paciente con síndrome de Sjögren primario

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.53

Treatment of mucosa-associated lymphoid tissue lymphoma in Sjogren's syndrome: a retrospective clinical study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.53

Clinical and histologic evidence of salivary gland restoration supports the efficacy of rituximab treatment in Sjögren's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.53

Increase of B cell-activating factor of the TNF family (BAFF) after rituximab treatment: insights into a new regulating system of BAFF production

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.53

Efficacy and safety of an intraoral electrostimulation device for xerostomia relief: a multicenter, randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.53

EULAR Sjogren's syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjogren's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.53

EULAR Sjogren's Syndrome Patient Reported Index (ESSPRI): development of a consensus patient index for primary Sjogren's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.53

A new system for grading recommendations in evidence based guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.53

Proteomic study of salivary peptides and proteins in patients with Sjögren's syndrome before and after pilocarpine treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.53

The efficacy of Xialine in patients with Sjögren's syndrome: a single-blind, cross-over study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.53

Comparison between new saliva stimulants in patients with dry mouth: a placebo-controlled double-blind crossover study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.53

Treatment of xerostomia with polymer-based saliva substitutes in patients with Sjögren's syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.53

A double-blind crossover trial of CMC- and mucin-containing saliva substitutes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.53

Hydroxypropyl methylcellulose for the treatment of severe dry eye associated with Sjögren's syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.53

Diclofenac sodium, 0.1% (Voltaren Ophtha), versus sodium chloride, 5%, in the treatment of filamentary keratitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.53

Recurrence after topical nonpreserved methylprednisolone therapy for keratoconjunctivitis sicca in Sjögren's syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.53

Topical cyclosporin treatment of keratoconjunctivitis sicca in secondary Sjögren's syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.53

Analysis of topical cyclosporine treatment of patients with dry eye syndrome: effect on conjunctival lymphocytes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.53

A follow-up study of the progress of keratoconjunctivitis sicca and response to treatment in primary Sjögren's syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.53

Pilocarpine treatment in a mixed cohort of xerostomic patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.53

Oral pilocarpine HCl stimulates labial (minor) salivary gland flow in patients with Sjögren's syndrome.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.53

Pilocarpine tablets for the treatment of dry mouth and dry eye symptoms in patients with Sjögren syndrome: a randomized, placebo-controlled, fixed-dose, multicenter trial. P92-01 Study Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.53

Sjögren's syndrome patients presenting with hypergammaglobulinemia are relatively unresponsive to cevimeline treatment.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.53

Efficacy prediction of cevimeline in patients with Sjögren's syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.53

Efficacy and safety of mizoribine for the treatment of Sjögren's syndrome: a multicenter open-label clinical trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.53

Efficacy and safety of rebamipide for the treatment of dry mouth symptoms in patients with Sjögren's syndrome: a double-blind placebo-controlled multicenter trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.53

Zidovudine in primary Sjögren's syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.53

Patients with primary Sjögren's syndrome treated for two months with evening primrose oil

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.53

Effect of the H2 receptor antagonist nizatidine on xerostomia in patients with primary Sjögren's syndrome.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.53

Treatment of primary Sjögren's syndrome with low-dose human interferon alfa administered by the oromucosal route: combined phase III results

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.53

Single-blinded controlled trial of low-dose oral IFN-alpha for the treatment of xerostomia in patients with Sjögren's syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.53

RETRACTED: Infliximab in patients with primary Sjögren's syndrome: a pilot study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.53

Etanercept in Sjögren's syndrome: a twelve-week randomized, double-blind, placebo-controlled pilot clinical trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.53

Improvement of Sjögren's syndrome after two infusions of rituximab (anti-CD20)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.53

Treatment approaches in primary Sjogren syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.53

Comparison of autologous serum and umbilical cord serum eye drops for dry eye syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.53

Fibromyalgia in Italian patients with primary Sjögren’s syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.53

Efficacy of low-dose prednisolone maintenance for saliva production and serological abnormalities in patients with primary Sjögren's syndrome.

31 March 2020

1 reference

12 December 2020

A double-blind, cross-over, study of oral N-acetylcysteine in Sjögren's syndrome

1 reference

12 December 2020

Saliva substitute in xerostomic patients with primary Sjögren's syndrome: a single-blind trial

1 reference

12 December 2020

Treatment of primary Sjögren's syndrome with hydroxychloroquine: a retrospective, open-label study.

1 reference

12 December 2020

Influence of clinical and immunological parameters on the health-related quality of life of patients with primary Sjögren's syndrome.

1 reference

12 December 2020

Cyclosporin a therapy in patients with primary Sjögren's syndrome: results at one year

1 reference

12 December 2020

Interferon alpha-2 (IFN alpha 2) increases lacrimal and salivary function in Sjögren's syndrome patients. Preliminary results of an open pilot trial versus OH-chloroquine.

1 reference

12 December 2020

Clinical evaluation of a commercially available oral moisturizer in relieving signs and symptoms of xerostomia in postirradiation head and neck cancer patients and patients with Sjögren's syndrome

1 reference

12 December 2020

Treatment of primary Sjögren's syndrome with D-penicillamine: a pilot study.

1 reference

12 December 2020

Off-label use of rituximab in 196 patients with severe, refractory systemic autoimmune diseases

1 reference

12 December 2020

A double blind placebo controlled trial of azathioprine in the treatment of primary Sjögren's syndrome

1 reference

12 December 2020

High prevalence of serum metabolic alterations in primary Sjögren's syndrome: influence on clinical and immunological expression

1 reference

12 December 2020

Methotrexate in primary Sjögren's syndrome.

1 reference

12 December 2020

Etanercept in the treatment of patients with primary Sjögren's syndrome: a pilot study

1 reference

12 December 2020

Candida albicans levels in patients with Sjögren's syndrome before and after long-term use of pilocarpine hydrochloride: a pilot study

1 reference

12 December 2020

Prednisone and piroxicam for treatment of primary Sjögren's syndrome

1 reference

12 December 2020

Treatment of xerostomia in patients with primary Sjögren's syndrome with sulfarlem

1 reference

12 December 2020

Ultrasound assessment of salivary glands in patients with primary Sjögren's syndrome treated with rituximab: Quantitative and Doppler waveform analysis.

1 reference

12 December 2020